Anti-Glial Fibrillary Acidic Protein (GFAP) Antibody

Glial Fibrillary Acidic Protein (GFAP) was discovered by Amico Bignami and co-workers as a major fibrous protein of multiple sclerosis plaques (1) . It was subsequently found to be a member of the 10nm or intermediate filament (IF) family, specifically the IF family Class III, which also includes peripherin, desmin and vimentin. GFAP is strongly and specifically expressed in astrocytes and certain other astroglia in the CNS, in satellite cells, peripheral ganglia, and in non-myelinating Schwann cells in peripheral nerves. In many damage and disease states GFAP expression is heavily upregulated in astrocytes. In addition, neural stem cells frequently strongly express GFAP. Point mutations in the protein coding region of the GFAP gene lead to Alexander disease which is characterized by the presence of abnormal astrocytes containing GFAP protein aggregates known as Rosenthal fibers (2) .

Wu:fb34h11 antibody, ALXDRD antibody, cb345 antibody, etID36982.3 antibody, FLJ42474 antibody, FLJ45472 antibody, GFAP antibody, GFAP_HUMAN antibody, gfapl antibody, Glial fibrillary acidic protein antibody, Intermediate filament protein antibody, wu:fk42c12 antibody, xx:af506734 antibody, zgc:110485 antibody

For research use only. Not intended for therapeutic or diagnostic use. Use of all products is subject to our terms and conditions, which can be viewed on our website.

Recommended that the undiluted antibody be aliquoted into smaller working volumes (10-30 uL/vial depending on usage) upon arrival and stored long term at -20° C or -80° C, while keeping a working aliquot stored at 4° C for short term. Avoid freeze/thaw cycles. Stable for at least 1 year.